• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    6/23/23 1:37:41 PM ET
    $BBLN
    $BDRX
    $BNTC
    $CFMS
    Medical/Nursing Services
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBLN alert in real time by email

    Gainers

    • Conformis (NASDAQ:CFMS) shares rose 86.2% to $2.16 during Friday's regular session. Trading volume for this security as of 13:37 EST is 5.0 million, which is 7195.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $16.1 million.
    • SCWorx (NASDAQ:WORX) shares moved upwards by 59.05% to $0.57. As of 13:37 EST, this security is trading at a volume of 60.1 million shares, making up 1862.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.4 million.
    • OncoSec Medical (NASDAQ:ONCS) stock rose 30.82% to $0.28. As of 13:37 EST, this security is trading at a volume of 45.0 million shares, making up 3523.4% of its average full-day volume over the last 100 days. The company's market cap stands at $1.6 million.
    • Surgalign Holdings (NASDAQ:SRGA) shares moved upwards by 26.99% to $0.26. Surgalign Holdings's stock is trading at a volume of 53.8 million shares as of 13:37 EST. This is 5309.0% of its average full-day volume over the last 100 days. The company's market cap stands at $2.3 million.
    • Etao International Co (NASDAQ:ETAO) shares increased by 23.5% to $0.84. As of 13:37 EST, Etao International Co's stock is trading at a volume of 1.7 million, which is 340.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $85.8 million.
    • Pieris Pharmaceuticals (NASDAQ:PIRS) shares rose 18.54% to $0.26. As of 13:37 EST, Pieris Pharmaceuticals's stock is trading at a volume of 4.8 million, which is 429.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $21.4 million.

    Losers

    • Babylon Holdings (NYSE:BBLN) shares decreased by 24.1% to $0.47 during Friday's regular session. Trading volume for this security as of 13:37 EST is 658.0K, which is 96.7% of its average full-day volume over the last 100 days. The company's market cap stands at $12.0 million.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) shares decreased by 20.38% to $0.06. Biodexa Pharmaceuticals's stock is trading at a volume of 6.2 million shares as of 13:37 EST. This is 123.6% of its average full-day volume over the last 100 days. The company's market cap stands at $1.1 million.
    • Beyond Air (NASDAQ:XAIR) shares declined by 19.37% to $4.6. As of 13:37 EST, Beyond Air's stock is trading at a volume of 2.1 million, which is 598.7% of its average full-day volume over the last 100 days. The company's market cap stands at $138.4 million. As per the press release, Q4 earnings came out yesterday.
    • Stoke Therapeutics (NASDAQ:STOK) stock decreased by 15.31% to $11.12. As of 13:37 EST, Stoke Therapeutics's stock is trading at a volume of 181.6K, which is 76.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $491.3 million.
    • Oramed Pharmaceuticals (NASDAQ:ORMP) shares fell 14.81% to $3.19. As of 13:37 EST, Oramed Pharmaceuticals's stock is trading at a volume of 745.5K, which is 82.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $127.8 million.
    • Benitec Biopharma (NASDAQ:BNTC) shares decreased by 14.57% to $0.19. The current volume of 540.0K shares is 177.9% of Benitec Biopharma's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $5.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BBLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBLN
    $BDRX
    $BNTC
    $CFMS

    CompanyDatePrice TargetRatingAnalyst
    Stoke Therapeutics Inc.
    $STOK
    2/24/2026$40.00Outperform
    Wolfe Research
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    Stoke Therapeutics Inc.
    $STOK
    1/5/2026$35.00Buy
    Chardan Capital Markets
    Stoke Therapeutics Inc.
    $STOK
    7/18/2025$30.00Buy
    Jefferies
    Beyond Air Inc.
    $XAIR
    7/17/2025$11.00Buy
    D. Boral Capital
    Benitec Biopharma Inc.
    $BNTC
    7/7/2025Buy
    TD Cowen
    Stoke Therapeutics Inc.
    $STOK
    12/20/2024$24.00Buy
    Chardan Capital Markets
    Benitec Biopharma Inc.
    $BNTC
    12/16/2024$28.00Buy
    H.C. Wainwright
    More analyst ratings

    $BBLN
    $BDRX
    $BNTC
    $CFMS
    SEC Filings

    View All

    SEC Form 8-K filed by Stoke Therapeutics Inc.

    8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)

    3/3/26 4:11:18 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oramed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)

    2/20/26 4:26:58 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SCHEDULE 13G - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    2/17/26 9:55:22 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLN
    $BDRX
    $BNTC
    $CFMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Krainer Adrian R. sold $286,715 worth of shares (7,229 units at $39.66), decreasing direct ownership by 2% to 316,545 units (SEC Form 4)

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    3/4/26 4:28:40 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF MEDICAL OFFICER Ticho Barry

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    2/19/26 4:25:56 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Smith Ian F

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    2/19/26 4:24:03 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLN
    $BDRX
    $BNTC
    $CFMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Stoke Therapeutics with a new price target

    Wolfe Research initiated coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $40.00

    2/24/26 7:56:29 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets resumed coverage on Stoke Therapeutics with a new price target

    Chardan Capital Markets resumed coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $35.00

    1/5/26 9:19:09 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLN
    $BDRX
    $BNTC
    $CFMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

    –Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase 3 EMPEROR study– Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New England Journal of Medicine (NEJM). The publication includes results from two completed Phase 1/2a and ongoing open-label extension (OLE) studies that demonstra

    3/4/26 5:06:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

    –Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase 3 EMPEROR study– BEDFORD, Mass. and CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) --  Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New England Journal of Medicine (NEJM). The publication includes results from two completed

    3/4/26 5:05:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    SCWorx Announces New SaaS and Data Management Customer Supporting a Prominent Southeastern Healthcare Provider's Workday Platform

    New York, NY, March 04, 2026 (GLOBE NEWSWIRE) -- SCWorx Corp. (NASDAQ:SCWX), a leading provider of data management, analytics, and interoperability solutions for healthcare organizations, today announced that it has signed a new SaaS and data management customer agreement with a prominent Southeastern healthcare provider in support of its implementation and ongoing optimization of its Workday platform. The health system's integrated delivery network (IDN) comprises over 700 beds across multiple acute care hospitals and outpatient facilities, serving communities throughout the region. Under the agreement, SCWorx will provide its cloud-based data management and governance solutions to suppo

    3/4/26 10:11:22 AM ET
    $SCWX
    $WORX
    Computer Software: Prepackaged Software
    Technology
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $BBLN
    $BDRX
    $BNTC
    $CFMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Suvretta Capital Management, Llc bought $1,903,133 worth of shares (144,223 units at $13.20) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/29/25 7:31:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $538,972 worth of shares (46,141 units at $11.68) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/22/25 7:45:03 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $19,999,994 worth of shares (1,481,481 units at $13.50) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    11/10/25 9:51:33 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLN
    $BDRX
    $BNTC
    $CFMS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $BBLN
    $BDRX
    $BNTC
    $CFMS
    Leadership Updates

    Live Leadership Updates

    View All

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

    HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Dr. Sharon Mates to the board of directors (BOD) of the Company, effective November 2, 2025. "We are delighted to welcome Dr. Sharon Mates to Benitec's Board of Directors," said Jerel Banks, M.D., Ph.D., Chairman and Chief Executive Officer of Benitec Biopharma. "Dr. Mates brings exceptional leadership experience in building successful biotechnology c

    11/3/25 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interim results for the six months ended June 30, 2025

    September 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company's website at www.biodexapharma.com. OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2025: Allowance by the US Patent and Trademark Office of patent application No. 17/391-495 "Oral Rapamycin Nanopart

    9/12/25 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLN
    $BDRX
    $BNTC
    $CFMS
    Financials

    Live finance-specific insights

    View All

    Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

    Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed's current returns to $118 million on its original $99.5 million Scilex investment, with additional returns expected from the remaining convertible notes, warrants, and royalties. Oramed retains a $27 million note and a $12 million convertible note with Scilex, convert

    1/7/26 8:55:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oramed Reports Fiscal Third Quarter 2025 Financial Results

    Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial results for the nine months ended September 30, 2025. Nine-Month Period 2025 Financial Highlights: Net income (pre-tax) of $65.0 million, compared to a net loss of $6.1 million in the same period last yearCompleted

    11/17/25 8:56:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

    NEW YORK, Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent, and declared a dividend of one common stock purchase right (a "Right") on each outstanding share of its common stock, par value $0.012 per share (the "Common Stock"), of the Company.  The Rights are designed to assure that all stockholders of the Company receive fair and equal treatment in the event of a hostile takeover of the Company, to guard against tactics designed to gain cont

    11/17/25 8:50:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBLN
    $BDRX
    $BNTC
    $CFMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pieris Pharmaceuticals Inc.

    SC 13G/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

    12/17/24 5:42:35 PM ET
    $PIRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary